We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Photodynamic Therapy With Verteporfin for Corneal Neovascularization

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00471406
First Posted: May 9, 2007
Last Update Posted: October 17, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Chonnam National University Hospital
  Purpose

Purpose: To investigate the efficacy of photodynamic therapy with verteporfin for the treatment of patients with corneal neovascularization.

Design: Prospective, non-comparative case series. Participants: Eighteen eyes of 18 patients with stable corneal neovascularization who were refractory to conventional treatment.

Methods: The patients were treated with photodynamic therapy with verteporfin (6 mg/m2). Five patients were treated following penetrating keratoplasty, and 2 patients were treated before penetrating keratoplasty. Best corrected visual acuity and anterior segment photography were performed before and after treatment. The length of cumulative blood vessels and area of corneal neovascularization were measured.

Main outcome measures: Vascular occlusion, best corrected visual acuity, cumulative blood vessel length, and corneal neovascularization area.


Condition Intervention
Corneal Neovascularization Procedure: Photodynamic Therapy with Verteporfin

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Chonnam National University Hospital:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   35 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Patients with clinically stable corneal neovascularization who were not improved after treatment with 1% prednisolone acetate eyedrops instilled 4 times a day for at least 1 month

Exclusion Criteria:

  • Individuals who had active keratitis with vessel proliferation, uncontrolled inflammation, active hepatitis or clinically significant liver disease, or porphyria or other porphyrin sensitivity
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00471406


Sponsors and Collaborators
Chonnam National University Hospital
Investigators
Study Director: Kyung chul Yoon, MD Chonnam natianl university hospital
  More Information

ClinicalTrials.gov Identifier: NCT00471406     History of Changes
Other Study ID Numbers: CPDT-0001
First Submitted: May 8, 2007
First Posted: May 9, 2007
Last Update Posted: October 17, 2008
Last Verified: October 2008

Additional relevant MeSH terms:
Neovascularization, Pathologic
Corneal Neovascularization
Metaplasia
Pathologic Processes
Corneal Diseases
Eye Diseases
Verteporfin
Photosensitizing Agents
Dermatologic Agents